Ryosuke Sakemi

Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

Taku Kobayashi, Satoshi Motoya, Shirô Nakamura et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 63 citations

Inflammation, Anti-inflammatory, Allergy +4

Evaluation of Serum Leucine‐Rich Alpha‐2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease

Tetsuhiro Yoshimura, Keiichi Mitsuyama, Ryosuke Sakemi et al. · Mediators of Inflammation · 2021 · 34 citations · Full text

A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn’s disease

Shigeki Bamba, Ryosuke Sakemi, Toshimitsu Fujii et al. · Journal of Gastroenterology · 2020 · 26 citations

Retrospective Study, Functional Gastrointestinal Disorder, Crohn ’ +5

X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues

Ryosuke Sakemi, Hirohisa Yano, Sachiko Ogasawara et al. · Oncology Reports · 2007 · 23 citations · Full text

Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease

Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba et al. · Intestinal Research · 2018 · 17 citations · Full text